e-learning
resources
ERJ
2010
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Quality of life and dyspnoea in patients treated with bosentan for idiopathic pulmonary fibrosis (BUILD-1)
Raghu G., King T. E. Jr, Behr J., Brown K. K., du Bois R. M., Leconte I., Roux S., Swigris J.
Source:
Eur Respir J 2010; 35: 118-123
Journal Issue:
January
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Raghu G., King T. E. Jr, Behr J., Brown K. K., du Bois R. M., Leconte I., Roux S., Swigris J.. Quality of life and dyspnoea in patients treated with bosentan for idiopathic pulmonary fibrosis (BUILD-1). Eur Respir J 2010; 35: 118-123
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
ERS clinical practice guidelines on treatment of sarcoidosis
Related content which might interest you:
Effect of nintedanib on cough and health related quality of life in patients with idiopathic pulmonary fibrosis
Source: International Congress 2016 – IPF: from pathogenesis to treatment I
Year: 2016
Impact of riociguat on health-related quality of life (HRQoL) in patients with chronic thromboembolic pulmonary hypertension (CTEPH)
Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment
Year: 2013
Quality of life in patients with idiopathic pulmonary fibrosis
Source: Eur Respir J 2005; 26: Suppl. 49, 30s
Year: 2005
Quality of life of idiopathic pulmonary fibrosis patients
Source: International Congress 2017 – IPF: from the bench to the bedside
Year: 2017
Patients’ expectations and quality of life before introduction of pirfenidone used in idiopathic pulmonary fibrosis.
Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments
Year: 2018
Impact of riociguat on health-related quality of life (HRQoL) in patients with pulmonary arterial hypertension (PAH)
Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment
Year: 2013
Health-related quality of life in patients with idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Diffuse parenchymal lung disease II
Year: 2013
Prognosis symptoms, quality of life and comorbidity relationship with cough in patients with idiopathic pulmonary fibrosis
Source: International Congress 2019 – Comorbidities of idiopathic pulmonary fibrosis
Year: 2019
The burden of idiopathic pulmonary fibrosis reported by patients and carers in Ireland
Source: International Congress 2015 – IPF: clinical aspects
Year: 2015
The development of a measure to better understand patient experiences with pirfenidone and nintedanib for the treatment of idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2016 – IPF: from pathogenesis to treatment I
Year: 2016
Assessing quality of life of idiopathic pulmonary fibrosis patients: the INSTAGE study
Source: Breathe, 15 (2) 144; 10.1183/20734735.0016-2019
Year: 2019
Sleep quality among patients with idiopathic pulmonary fibrosis
Source: International Congress 2015 – Interstitial lung diseases II
Year: 2015
The effect of pulmonary rehabilitation on exercise tolerance pulmonary function dyspnea and quality of life in patients with idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –The best posters in pulmonary rehabilitation
Year: 2013
Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium
Source: Eur Respir J 2002; 19: 209-216
Year: 2002
Health-related quality of life and health status among patients with sarcoidosis, chronic obstructive pulmonary disease and interstitial lung disease
Source: International Congress 2018 – Granulomatous disorders: heterogeneous diseases with variable management
Year: 2018
Quality of life (HQoL) and well-being in patients with idiopathic pulmonary fibrosis (IPF): the role of portable oxygen
Source: Annual Congress 2008 - Management of idiopathic pulmonary fibrosis: what can we learn from the pathophysiology?
Year: 2008
The effect of pulmonary rehabilitation on health-related quality of life in patients with pulmonary sarcoidosis
Source: International Congress 2018 – Telehealth, home rehabilitation and specific adaptations to exercise interventions in different settings
Year: 2018
Relationship between dyspnea levels and health-related quality of life (HRQoL) in patients with stable chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2003; 22: Suppl. 45, 240s
Year: 2003
Analysis of the level of dyspnea and health-related quality of life (HRQoL) in patients with stable chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2002; 20: Suppl. 38, 250s
Year: 2002
mMRC dyspnoea scale indicates impaired quality of life and increased pain in patients with idiopathic pulmonary fibrosis
Source: ERJ Open Res, 3 (4) 00084-2017; 10.1183/23120541.00084-2017
Year: 2017
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept